RUPP PI PDD: Drug and Behavioral Therapy for Children With Pervasive Developmental Disorders
Tracking Information | |
---|---|
First Received Date ICMJE | March 24, 2004 |
Last Updated Date | May 5, 2008 |
Start Date ICMJE | February 2004 |
Primary Completion Date | |
Current Primary Outcome Measures ICMJE |
|
Original Primary Outcome Measures ICMJE | Same as current |
Change History | Complete list of historical versions of study NCT00080145 on ClinicalTrials.gov Archive Site |
Current Secondary Outcome Measures ICMJE |
|
Original Secondary Outcome Measures ICMJE | Same as current |
Current Other Outcome Measures ICMJE | |
Original Other Outcome Measures ICMJE | |
Descriptive Information | |
Brief Title ICMJE | RUPP PI PDD: Drug and Behavioral Therapy for Children With Pervasive Developmental Disorders |
Official Title ICMJE | Risperidone and Behavioral Therapy in Treatment of Children and Adolescents With Autistic Disorder |
Brief Summary | This 24-week study will compare the safety and effectiveness of medication treatment alone (risperidone or aripiprazole) to medication treatment in combination with a parent management training program. |
Detailed Description | PDD can be a profoundly disabling condition across social, emotional, and academic domains. Safe and effective treatments for PDD are needed. Participants are randomly assigned to receive either risperidone plus parent management training or risperidone alone for 24 weeks. Participants who show deterioration at Week 4 will be offered an alternative mediation treatment, aripiprazole. These participants will remain in their original treatment group (either med alone or med plus parent management training). After 6 months of treatment (Week 24), participants who respond to their treatment will be gradually discontinued from their medication treatment to learn if the response can be sustained without continued medication treatment (This phase of the study was ended in Nov. 2006) Adaptive and behavioral outcomes are assessed during the study. |
Study Type ICMJE | Interventional |
Study Phase | |
Study Design ICMJE | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
Condition ICMJE | Child Development Disorders, Pervasive |
Intervention ICMJE |
|
Study Arm (s) | |
Publications * |
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|
Recruitment Information | |
Recruitment Status ICMJE | Completed |
Enrollment ICMJE | 124 |
Completion Date | September 2007 |
Primary Completion Date | |
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
Gender | Both |
Ages | 4 Years to 13 Years |
Accepts Healthy Volunteers | No |
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects |
Location Countries ICMJE | United States |
Administrative Information | |
NCT Number ICMJE | NCT00080145 |
Other Study ID Numbers ICMJE | U10 MH66764, U10 MH66766, U10 MH66768, DDTR BD-DD |
Has Data Monitoring Committee | Yes |
Responsible Party | |
Study Sponsor ICMJE | National Institute of Mental Health (NIMH) |
Collaborators ICMJE | |
Investigators ICMJE | |
Information Provided By | National Institute of Mental Health (NIMH) |
Verification Date | May 2008 |
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |